1419 (1419) Fair Value & Analysis

Healthcare · Market cap HK$277M

1 1419 1419 · HK

PriceHK$0.7300

Fair ValueHK$1.53

Upside+109.6%

Quality62/100

Watch 1419 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$1.14 – HK$1.91

Fair value as of: Jul 2, 2026

From 26 valuation models · updated today

Share price −6.4% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.7200 – HK$1.32 · fair‑value band HK$1.14 – HK$1.91 · the HK$0.7300 price screens below the HK$1.53 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

1419 (1419) currently trades at HK$0.7300, while our model-based Fair Value estimate is HK$1.53 — implying the stock looks roughly 109.6% undervalued today. We read business quality at 62/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Over the trailing twelve months, 1419 generated revenue of HK$671M at a net margin of 4.1%. Revenue grew 8.4% year over year. It earns a return on equity of 3.7%. The balance sheet holds a net cash position of HK$305M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$671M

Revenue growth (YoY) +8.4%

Net margin 4.1%

Return on equity 3.7%

Free cash flow HK$89.5M FY2025

P/E ratio 10.4

More key figures

Operating margin 7.1%

EPS (TTM) HK$0.0300

Dividend yield 4.1%

EPS growth (YoY) +9.1%

Net cash HK$305M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

1419 reported revenue of HK$644M in FY2025 versus HK$655M in FY2021, a compound −0.4%/yr. Reported net income was HK$26.3M in FY2025, compounding −34.7%/yr from FY2021.

Revenue −0.4%/yr

FY21 HK$655M

FY22 HK$1.1B

FY23 HK$1.0B

FY24 HK$591M

FY25 HK$644M

Net income −34.7%/yr

FY21 HK$144M

FY22 HK$375M

FY23 HK$181M

FY24 HK$24.2M

FY25 HK$26.3M

Is 1419 fairly valued? → Check now

Similar stocks

6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
HCA Healthcare, Inc H1CA34	R$95.75	R$123.65	+29%
Fresenius SE FSNUY	$11.30	$8.61	-24%
5225 5225	8.67 MYR	3.08 MYR	-64%
IHHHF IHHHF	$1.71	$0.7400	-57%
Tenet Healthcare Corporation THC	$162.06	$282.55	+74%
Rede D'Or São Luiz S.A RDOR3	R$32.76	R$30.33	-7%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 1419 (1419) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$1.53 versus a price of HK$0.7300 — about +110% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 1419?

Our model-based fair value for 1419 is HK$1.53 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.7300.

What is the quality score of 1419?

1419 has a Quality Score of 62/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 1419 (1419)?

1419 reported trailing-twelve-month revenue of about HK$671M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 1419?

The net profit margin of 1419 is about 4.1%, meaning it keeps roughly 4.1% of revenue as net income. Based on the latest reported figures.

Does 1419 pay a dividend?

1419 currently shows a dividend yield of about 4.11% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.